Neuraxis (NRXS) Accumulated Expenses (2022 - 2025)
Neuraxis (NRXS) posted Accumulated Expenses of $692683.0 for Q4 2025, down 64.59% sequentially from $2.0 million in Q3 2025, and down 45.08% YoY from $1.3 million in Q4 2024.
Neuraxis (NRXS) Accumulated Expenses (2022 - 2025) Analysis & Trends
Neuraxis has reported Accumulated Expenses for 4 years, with the latest figure at $692683.0 in Q4 2025.
- Quarterly Accumulated Expenses fell 45.08% year-over-year to $692683.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $692683.0 (down 45.08% YoY) and the FY2025 annual result came in at $692683.0, down 45.08% from the prior year.
- Accumulated Expenses retreated to $692683.0 in Q4 2025 per NRXS's latest filing, from $2.0 million in the prior quarter.
- Over five years, Accumulated Expenses peaked at $2.0 million in Q3 2025 and troughed at $66648.0 in Q4 2023.
- A 4-year average of $656479.0 and a median of $578097.5 in 2023 frame the typical range for Accumulated Expenses.
- The sharpest annual moves came in 2023 and 2024: Accumulated Expenses slumped 92.01% in 2023, then surged 1792.51% in 2024.
- Over 4 years, Accumulated Expenses stood at $834062.0 in 2022, then plunged by 92.01% to $66648.0 in 2023, then soared by 1792.51% to $1.3 million in 2024, then plunged by 45.08% to $692683.0 in 2025.
- According to Business Quant data, Accumulated Expenses over the past three periods registered $692683.0, $2.0 million, and $66648.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Neuraxis | 74.54 Mn | 66.21 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 692,683.00 |
| Sep 30, 2025 | 1.96 Mn |
| Jun 30, 2025 | 66,648.00 |
| Mar 31, 2025 | 66,648.00 |
| Dec 31, 2024 | 1.26 Mn |
| Sep 30, 2024 | 1.17 Mn |
| Jun 30, 2024 | 66,648.00 |
| Mar 31, 2024 | 816,480.00 |
| Dec 31, 2023 | 66,648.00 |
| Sep 30, 2023 | 417,390.00 |
| Jun 30, 2023 | 463,512.00 |
| Dec 31, 2022 | 834,062.00 |